Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

Presentation AHA 2024

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Presenter: Kausik K. Ray

November 17, 2024

Presentation AHA 2024

Efficacy and safety of EdoxabaN in anticoagulant therapy after surgical Bioprosthetic vALVe replacement

Presenter: Chisato Izumi

November 17, 2024

Presentation TCT 2024

TCT 763: Trajectories of Adherence to Secondary Prevention Pharmacotherapy After Coronary Catheterization: A Retrospective Population-Based Study

Presenter: Leon Heitmann

October 30, 2024

Presentation TCT 2024

Debate Con: Never

Presenter: Dominick Angiolillo

October 30, 2024

Presentation TCT 2024

Debate Pro: Always

Presenter: Marco Valgimigli

October 30, 2024

Presentation TCT 2024

TCT 10: Interference of Fentanyl in the Pharmacodynamics and Pharmacokinetics of Ticagrelor: A Meta-Analysis of Randomized Trials

Presenter: BERNARDO KREMER

October 27, 2024

Presentation ESC 2024

OCEANIC-AF: Asundexian vs. Apixaban in Patients with Atrial Fibrillation

Presenter: Manesh R. Patel

September 01, 2024

Presentation ESC 2024

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

Presenter: Gi-Byoung Nam

September 01, 2024

Presentation ESC 2024

NOTION-3: PCI in patients undergoing transcatheter aortic valve implantation

Presenter: Jacob Lønborg

August 31, 2024

Presentation EuroPCR 2024

One-month DAPT followed by 5-month Ti - cagrelor monotherapy in acute coronary syndromes with DCB - results from REC-CAGEFREE II

Presenter: Ling Tao

May 15, 2024

Presentation EuroPCR 2024

Methodological Insight: REC-CAGEFREE II Trial

Presenter: Robert Byrne

May 14, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

Presentation ACC 2024

Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial

Presenter: Gregg W Stone

April 07, 2024

Presentation ACC 2024

Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy

Presenter: Yousuf Razvi

April 06, 2024

Presentation ACC 2024

ApoA-I Event ReducinG in Ischemic Syndromes II (AEGIS-II) Trial

Presenter: C. Michael Gibson

April 06, 2024

Presentation Cardiovascular Interventions 2023

ICYMI: Drug Coated Balloons Have FINALLY Arrived: Here’s How I’m Going to Use Them!

Presenter: Ajay J. Kirtane

November 10, 2023

Advertisement

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Efficacy and safety of EdoxabaN in anticoagulant therapy after surgical Bioprosthetic vALVe replacement

TCT 763: Trajectories of Adherence to Secondary Prevention Pharmacotherapy After Coronary Catheterization: A Retrospective Population-Based Study

Debate Con: Never

Debate Pro: Always

TCT 10: Interference of Fentanyl in the Pharmacodynamics and Pharmacokinetics of Ticagrelor: A Meta-Analysis of Randomized Trials

OCEANIC-AF: Asundexian vs. Apixaban in Patients with Atrial Fibrillation

Edoxaban-Based Long-Term Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Disease: The EPIC-CAD Randomized Clinical Trial

NOTION-3: PCI in patients undergoing transcatheter aortic valve implantation

One-month DAPT followed by 5-month Ti - cagrelor monotherapy in acute coronary syndromes with DCB - results from REC-CAGEFREE II

Methodological Insight: REC-CAGEFREE II Trial

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Principal Results From the Double-blind, Placebo-controlled ULTIMATE-DAPT Trial

Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy

ApoA-I Event ReducinG in Ischemic Syndromes II (AEGIS-II) Trial

ICYMI: Drug Coated Balloons Have FINALLY Arrived: Here’s How I’m Going to Use Them!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content